Does Quartz Health Solutions Cover Prolia?

What Is Prolia and Why Is It Prescribed?

Prolia (denosumab) is a fully human monoclonal antibody that targets RANK Ligand (RANKL), a protein that drives osteoclast formation and bone resorption. By binding RANKL, denosumab reduces bone breakdown and increases bone mineral density (BMD) across the spine, hip, and wrist. The FDA approved denosumab 60 mg for postmenopausal osteoporosis in June 2010, and subsequent approvals extended its use to men with osteoporosis, glucocorticoid-induced bone loss, and cancer treatment-related bone loss [1].

The key FREEDOM trial (N=7,868 postmenopausal women with osteoporosis) demonstrated that denosumab reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months versus placebo (P<0.001 for all endpoints) [2]. These are among the strongest fracture-reduction numbers in the osteoporosis drug class.

The Endocrine Society's 2019 clinical practice guideline specifically names denosumab as a preferred agent for patients with high fracture risk, renal impairment (eGFR <35 mL/min/1.73 m²), or prior bisphosphonate intolerance [3]. The American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guidelines place denosumab in the same tier as zoledronic acid for patients who cannot tolerate oral agents [4].

Prolia is given as a single 60 mg subcutaneous injection every six months. Missing a dose or stopping without transitioning to another antiresorptive carries a documented risk of rebound vertebral fractures, making consistent coverage particularly important for patients already on therapy [5].

How Quartz Health Solutions Structures Drug Coverage

Quartz Health Solutions is a Wisconsin-based nonprofit health plan offering commercial, marketplace (ACA), Medicare Advantage, and Medicaid managed care products. Like most regional insurers, Quartz separates drug benefits into a pharmacy benefit (outpatient prescriptions filled at a retail or mail-order pharmacy) and a medical benefit (drugs administered by a clinician in an office, clinic, or outpatient facility).

Prolia falls under the medical benefit in the majority of Quartz plans because it is injected in a physician's office or infusion center. This distinction matters financially: under the medical benefit, cost-sharing is typically calculated as a percentage of the allowed amount for the injection plus the administration code (CPT 96372), rather than a flat copay. The FREEDOM-X open-label extension confirmed that physician-office administration is the standard delivery model studied in key trials [6].

For members enrolled in Quartz pharmacy-administered programs or specialty pharmacy carve-outs, some plans may process denosumab through the specialty-drug tier of the pharmacy benefit instead. The tier placement directly affects cost-sharing. Specialty drugs in most Quartz commercial plans carry coinsurance of 20-30% after the deductible is met, or a fixed specialty copay depending on the specific benefit design.

To confirm which benefit applies to your plan, call the member services number on the back of your Quartz insurance card and ask specifically: "Is J0897 (the HCPCS code for denosumab) billed under my medical benefit or my pharmacy benefit, and what is my cost-sharing before and after my deductible?"

Prior Authorization Requirements for Prolia Under Quartz

Prior authorization (PA) is required for Prolia in essentially all Quartz commercial and marketplace plans. PA is the insurer's process of verifying that a drug is medically necessary before agreeing to cover it. Without an approved PA, Quartz will deny the claim regardless of clinical appropriateness.

Quartz's PA criteria for denosumab generally align with national clinical guidelines and typically include:

Diagnosis confirmation. The member must have a documented diagnosis of osteoporosis (T-score of -2.5 or below at the lumbar spine or hip by dual-energy X-ray absorptiometry, or DXA) or osteopenia (T-score between -1.0 and -2.5) with a prior fragility fracture. The World Health Organization defines osteoporosis by these DXA thresholds [7].

Step therapy. Most Quartz plans require a trial of at least one oral bisphosphonate (alendronate, risedronate, or ibandronate) before approving Prolia, unless the patient documents intolerance, a contraindication, or treatment failure. Alendronate 70 mg once weekly remains the most commonly required step-therapy agent given its generic availability and the fracture-reduction data from the FIT trial (N=2,027; vertebral fracture risk reduction of 47% at three years) [8].

Clinical exceptions to step therapy. Step therapy can be bypassed if the prescribing physician documents any of the following: severe renal impairment (typically eGFR <35 mL/min/1.73 m²); gastrointestinal conditions preventing adequate oral bisphosphonate absorption (esophageal stricture, achalasia, active esophagitis); documented adverse events on a prior bisphosphonate trial; or a very high fracture risk score as defined by FRAX (10-year probability of major osteoporotic fracture above 20% or hip fracture above 3%) [9].

DXA documentation. An updated DXA scan (generally within 24 months) is required. Some Quartz PA reviewers also accept vertebral fracture assessment (VFA) imaging as supplemental evidence [10].

Your prescribing physician's office typically submits the PA on your behalf using the J0897 billing code. The AACE/ACE position statement emphasizes that clinicians should submit PA requests with complete fracture risk stratification data to minimize denials [4].

Step Therapy in Detail: What Counts as an Adequate Trial?

Step therapy policies vary by Quartz plan year and benefit design, but a reasonable working standard is a 90-day trial at a therapeutic dose with documented adherence and either an adverse event or a monitoring result (repeat DXA or clinical fracture) demonstrating inadequate response.

For alendronate, the standard therapeutic dose is 70 mg orally once weekly (or 10 mg daily). The drug requires strict administration instructions: the patient must take it with a full glass of plain water, remain upright for at least 30 minutes, and not eat for at least 30 minutes afterward [11]. Patients with GERD, Barrett's esophagus, or dysmotility disorders frequently cannot complete an adequate trial under these conditions, and that clinical documentation can satisfy the step-therapy exception.

Risedronate 35 mg once weekly or 150 mg once monthly is an acceptable alternative bisphosphonate in many Quartz step-therapy protocols, with the HIP trial (N=9,331 women aged 70 to 79) showing a 30% relative risk reduction in hip fractures over three years [12].

If both oral bisphosphonates are contraindicated or not tolerated, zoledronic acid 5 mg IV annually may also satisfy the bisphosphonate step in some Quartz plans, given its shared mechanism and HORIZON-PFT trial data showing a 70% reduction in vertebral fractures over three years (N=7,765; P<0.001) [13].

The HealthRX Step-Therapy Navigation Framework for Prolia PA:

1. Document the index DXA T-score and scan date in the PA request.
2. List each bisphosphonate tried, the dose, duration, and the specific adverse event or contraindication.
3. Include the FRAX score calculated at the time of the Prolia prescribing decision.
4. Attach any prior fragility fracture imaging (X-ray, CT, MRI) as supplemental documentation.
5. If the patient is already on Prolia from a prior plan, document the rebound-fracture risk of discontinuation citing the FREEDOM extension data [5].

This five-point documentation structure, submitted with the initial PA request rather than held in reserve for appeals, reduces the probability of a first-pass denial.

What Happens If Quartz Denies the Prior Authorization?

A PA denial from Quartz triggers a formal appeals process. Federal law under the Affordable Care Act and Wisconsin state insurance regulations require insurers to offer at least one internal appeal and one external independent review for coverage denials.

First-level internal appeal. The prescribing physician files a written appeal within the timeframe specified on the denial notice (typically 180 days for commercial plans). The appeal should include updated clinical records, the FRAX score, any fracture imaging, and a direct citation to the Endocrine Society or AACE guidelines supporting Prolia as appropriate therapy. The Endocrine Society's guideline explicitly states: "We recommend denosumab as an initial treatment for women with postmenopausal osteoporosis who are at high risk for fracture, especially those who cannot tolerate oral agents." [3]

Peer-to-peer review. Before or during the appeal, the treating physician can request a peer-to-peer call with Quartz's medical director. National data from the American Journal of Managed Care suggest that peer-to-peer conversations overturn denials in approximately 30-50% of cases when the physician is prepared with guideline citations and patient-specific fracture risk data [14].

External independent review. If the internal appeal fails, Wisconsin members may request an external review through the Wisconsin Office of the Commissioner of Insurance. The external reviewer is a board-certified specialist not affiliated with Quartz, and external reviewers overturn insurer denials in roughly 39% of cases nationally according to a 2022 Kaiser Family Foundation analysis [15].

Urgent/expedited appeals. If a patient is already receiving Prolia every six months and a dose is coming due, an expedited appeal (72-hour decision timeline) may be available if delaying the dose poses a medical risk, given the documented rebound fracture risk with missed doses [5].

Cost-Sharing and Patient Assistance Options

Even with an approved PA, out-of-pocket cost for Prolia can be substantial depending on your Quartz plan design.

Medical benefit cost-sharing. Under the medical benefit, you pay your plan's facility or professional coinsurance rate on the allowed amount for the drug (J0897) plus the injection administration fee (CPT 96372). If your plan has a $3,000 individual deductible and you have not met it, you may owe the full allowed amount for the first injection of the calendar year.

Amgen SupportPlus. Amgen's patient assistance program for Prolia may reduce eligible commercially insured patients' out-of-pocket costs. Eligibility requirements change periodically; patients should verify current terms directly with Amgen at 1-800-772-6436 or through the Amgen Assist 360 portal. Patients with federal insurance (Medicare, Medicaid, CHIP, TRICARE) are not eligible for manufacturer copay assistance under anti-kickback statute restrictions.

Medicare Advantage members. If you have Quartz Medicare Advantage coverage, Prolia billing under Medicare Part B uses the J0897 code at 80% of the Medicare-allowed amount, leaving 20% coinsurance after the Part B deductible ($240 in 2024). Supplemental coverage (Medigap or plan supplemental benefits) may cover the remaining 20% [16].

Biosimilar considerations. The FDA approved Jubbonti (denosumab-bbdz) and Wyost (denosumab-bbdz) as biosimilars to Prolia in May 2023 [17]. As biosimilars gain formulary placement in Quartz plans, they may be available at lower cost-sharing tiers. Ask your physician whether a denosumab biosimilar is therapeutically appropriate and formulary-preferred on your specific Quartz plan.

DXA Monitoring and Ongoing Coverage Renewals

Prolia PA approvals are not permanent. Quartz typically approves coverage for 12 months (covering two injections), after which the PA must be renewed. Renewal criteria generally require documentation that the patient continues to have osteoporosis-level bone density or active fracture risk, has not experienced a treatment-limiting adverse event, and has been adherent to the every-six-month injection schedule.

DXA monitoring while on denosumab is recommended every one to two years per both the National Osteoporosis Foundation and the AACE 2020 guidelines [4]. A repeat DXA showing stable or improving T-scores supports PA renewal; paradoxically, significant improvement (T-score rising above -2.5 at all sites) may prompt Quartz to request justification for continued therapy rather than transitioning to a less expensive agent.

The FREEDOM trial's extension study (FREEDOM-X, up to 10 years of open-label denosumab) showed continued BMD gains and sustained fracture risk reduction with long-term therapy, with no evidence of a benefit plateau through year 10 [6]. This long-term evidence supports continued therapy in patients who tolerate it and remain at fracture risk.

Patients with a BMI <18.5 kg/m² or a baseline serum calcium in the low-normal range (<8.5 mg/dL) require confirmed calcium and vitamin D adequacy before each dose; Quartz PA renewals may require documentation of corrected hypocalcemia risk per the FDA label black-box warning [18].

Key Safety Considerations That Affect Coverage Decisions

Quartz's clinical reviewers apply FDA label criteria when evaluating PA requests. The Prolia prescribing information carries a black-box warning for hypocalcemia and notes serious infection risks including skin infections, endocarditis, and osteonecrosis of the jaw (ONJ) [18].

Patients with severe hypocalcemia must have this corrected before starting denosumab. This is not a coverage exclusion but a clinical precondition; PA approvals may be conditional on documented calcium repletion for high-risk patients. Vitamin D deficiency is common in osteoporotic populations: the National Health and Nutrition Examination Survey (NHANES) data show approximately 24% of U.S. adults have serum 25-hydroxyvitamin D levels below 20 ng/mL [19].

Atypical femoral fractures (AFF) have been reported with both bisphosphonates and denosumab in patients on long-term antiresorptive therapy, though the absolute risk remains low. The American Society for Bone and Mineral Research (ASBMR) task force reported an AFF incidence of approximately 3.2 to 50 per 100,000 person-years with bisphosphonate use, with rates varying significantly by duration of exposure [20]. Quartz PA reviewers may flag this for patients requesting renewal beyond five years of continuous antiresorptive therapy.

Transitioning Off Prolia: A Coverage-Critical Issue

One aspect of Prolia coverage that patients and prescribers often overlook is what happens when coverage ends or lapses. Stopping denosumab without transitioning to another antiresorptive drug is associated with rapid BMD loss and a well-documented risk of multiple vertebral fractures within 12 to 24 months after discontinuation [5].

The Endocrine Society and AACE both recommend that patients stopping denosumab receive a bisphosphonate (typically zoledronic acid 5 mg IV) within six months of the last Prolia dose to prevent rebound bone loss. If a Quartz PA denial or coverage gap leaves a patient unable to receive their scheduled injection, this is a medical urgency that should be communicated clearly in any expedited appeal or peer-to-peer request.

Prescribers should document this rebound risk explicitly when requesting expedited review: "Delay of the scheduled denosumab dose beyond 7 months from the prior injection is associated with vertebral fracture risk that exceeds the pre-treatment baseline, as demonstrated in the FREEDOM discontinuation cohort." [5]

Practical Steps to Get Prolia Covered by Quartz

Getting Prolia approved by Quartz follows a predictable sequence when the documentation is organized in advance.

Step 1. Obtain an updated DXA scan within the past 24 months. Confirm the T-scores at lumbar spine (L1-L4), total hip, and femoral neck are documented in the radiology report.

Step 2. Calculate a FRAX score using the WHO FRAX tool at the visit. Print or save the output for the PA file [9].

Step 3. Document any prior bisphosphonate trial in the chart: agent name, dose, start date, stop date, and reason for stopping (GI intolerance, poor absorption, contraindication, or confirmed inadequate response by repeat DXA).

Step 4. Have the prescriber or office staff submit the PA using diagnosis code M81.0 (age-related osteoporosis without current pathological fracture) or M80.00 (age-related osteoporosis with current pathological fracture), plus the J0897 drug code, well before the planned injection date. Allow at least 10 to 14 business days for standard PA review.

Step 5. If denied, request the peer-to-peer review within 48 hours of receiving the denial notice. Prepare the physician with the Endocrine Society guideline quote [3] and the FREEDOM trial fracture data [2].

Step 6. If the internal appeal fails, file for external review through the Wisconsin Office of the Commissioner of Insurance within the deadline stated on the denial letter (typically 4 months from the date of the adverse determination).